https://scholar.dgist.ac.kr/handle/20.500.11750/8969 -The conception, design and creation of combinatorial antibodies- 2026-09-13T08:28:41Z https://scholar.dgist.ac.kr/handle/20.500.11750/60676 Title: Engineering of tandem bispecific IL-7 receptor agonist antibody promoting selective T cell expansion Author(s): Park, Jun-Kook; Jung, Inseong; Lee, Seunghyun; Kim, Jisuk; Shin, Sanghee; Shin, Jiwon; Noh, Soojeong; Kwon, Dahye; Nam, Chaerin; Kim, Hyunwook; Choi, Hongsoo; Yea, Kyungmoo Abstract: Interleukin-7 (IL-7) is indispensable for T cell development and homeostasis, and clinical studies have demonstrated its ability to restore T cell numbers in lymphopenic conditions. However, the therapeutic application of IL-7 has been limited by its short half-life and potential immunogenicity of recombinant variants. To overcome these challenges, we engineered a fully human tandem bispecific antibody, TB4, that functions as a potent IL-7 receptor agonist by cis-targeting IL-7 receptor alpha (IL-7R alpha) and the common gamma chain (gamma c). The tetravalent tandem scFv-Fc architecture, coupled with optimized linker length, conferred markedly enhanced binding affinity and avidity compared to the knobs-into-holes bispecific format, with domain orientation designed to limit unintended gamma c binding. At the cellular level, TB4 engaged both receptor subunits and exhibited reduced internalization dynamics, features that are likely to contribute to the sustained STAT5 phosphorylation observed in primary human T cells. Functionally, TB4 supported long-term T cell survival and expansion, but selectively promoted the expansion of CD4+ memory subsets, especially effector memory cells re-expressing CD45RA populations, in contrast to the broader effects of native IL-7. Transcriptomic profiling further revealed that while both TB4 and IL-7 activated proliferative gene programs, TB4 uniquely drove an antiviral and innate immune signature. Collectively, these findings establish TB4 as a next-generation IL-7R agonist antibody with a differentiated mechanism of action and potential as a precision immunomodulator that can selectively expand and reprogram T cells. 2026-06-30T15:00:00Z https://scholar.dgist.ac.kr/handle/20.500.11750/60581 Title: IL-2 표면 발현 세포외 소포체를 유효성분으로 포함하는 암 질환 예방 또는 치료용 조성물 Author(s): 예경무; 정도경; 백문창 Abstract: The present invention relates to a composition for preventing or treating cancer, the composition containing IL-2 surface expression-extracellular vesicles as an active ingredient. According to the present invention, immune cells, in which useful cytokines have been expressed on the cell surface, and extracellular vesicles, preferably small extracellular vesicles (sEV), which are derived from the immune cells and have useful cytokines expressed on the surface were prepared using a lentiviral vector containing a cytokine-linker-a PDGF receptor transmembrane domain, and it was found that the extracellular vesicles increased proliferation and activity of cytotoxic T cells thereby increasing anti-cancer immune efficacy. Thus, the extracellular vesicles having the efficacy can be usefully utilized as a pharmaceutical composition for preventing or treating cancer, a pharmaceutical composition for co-administration with an anticancer drug, or a composition for delivering a drug or a physiologically active material. https://scholar.dgist.ac.kr/handle/20.500.11750/60372 Title: 면역 항암 활성 사이토카인을 스크리닝하는 방법 및 IL-15를 유효성분으로 포함하는 암 질환 예방 또는 치료용 조성물 Author(s): 강성민; 예경무; 백문창 Abstract: 본 발명은 암세포의 엑소좀 분비를 억제하거나 프로그램된 세포사멸-리간드의 발현을 억제하는 면역 항암 활성을 갖는 사이토카인을 스크리닝 하는 방법에 관한 것으로, 사이토카인을 암호화하는 유전자, 링커를 암호화하는 링커 도메인, 및 막관통 단백질을 암호화하는 막관통 도메인으로 구성된 벡터를 암세포에 형질전환함으로써, 엑소좀 분비와 관련된 유전자의 발현 수준 또는 PD-L1의 발현 수준을 억제하는 면역 항암 활성을 나타내는 사이토카인을 선별할 수 있으며, 선별된 사이토카인을 새로운 항암제로 제공한다. 또한, 본 발명은 위의 스크리닝 기법을 이용하여 선별한 IL-15, 이의 발현 촉진제 또는 활성화제를 유효성분으로 포함하는 암 질환 예방 또는 치료용 조성물에 관한 것으로, 본 발명에서는 암세포에 IL-15를 처리 시, 암세포 유래 엑소좀 분비가 억제되고, T 세포의 면역 회피를 유도하는 PD-L1의 발현이 억제되어 항암 효과가 증진되는 것을 확인하였으며, 암세포에 직접적으로 항암 효과를 나타내는 것을 확인하였다. IL-15가 세포독성 T 세포를 활성화시키고 면역관문 PD-1, CTLA-4를 감소시키며 면역세포 유래 엑소좀을 증진시켜 면역 항암 효과를 나타내는 것을 확인하였다. 이는 IL-15, 이의 발현 촉진제 또는 활성화제는 암 질환 예방 또는 치료용 조성물 등으로 유용하게 활용될 수 있다. https://scholar.dgist.ac.kr/handle/20.500.11750/60320 Title: 신규한 항-C-MPL 항체 및 이의 용도 Author(s): 김민정; 정지영; 예경무; 박세광; 신지원 Abstract: The present invention relates to a novel anti-C-MPL antibody and a use thereof, and specifically, to an anti-C-MPL antibody having an effect of increasing platelet production and its number through the maturation of megakaryocytes in the bone marrow, and a use thereof. The novel anti-C-MPL antibody (2R13) of the present invention is a polymer material and has a longer half-life than the conventional therapeutic agents, and it has the advantage of low self-antibody production and low immunogenicity as an antibody agent. In addition, it can be used as a therapeutic agent for thrombocytopenia by increasing the platelet level of patients suffering from chronic or complication-induced immune thrombocytopenia.